CPHA Canvax

"The Medicago COVID-19 vaccine (Covifenz) is the first virus-like particle (VLP) COVID-19 vaccine authorized in Canada. Medicago Covifenz was authorized for use in adults 18-64 years of age by Health Canada on February 24, 2022." - NACI Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)

Additional Authors: Shainoor J. Ismail, Kelsey Young, Matthew C Tunis, Beate Sander, and Robyn Harrison

Rating See Comments Ratings


Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Management,Allocation and Distribution,Storage and Handling Vaccine Safety and Development
Vaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
Program Planning and Delivery
Program Delivery and Evaluation
Vaccine Management
Allocation and Distribution
Storage and Handling


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.